Stefan Stein

Dr. Stefan Stein

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2006 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MOMarion G Ott
Marion G Ott
MSManfred Schmidt
Manfred Schmidt
KSKerstin Schwarzwaelder
Kerstin Schwarzwaelder
SSStefan Stein
Stefan Stein
USUlrich Siler
Ulrich Siler
MGManuel Grez
Manuel Grez

24 January 2010 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
SSStefan Stein
Stefan Stein
MOMarion G Ott
Marion G Ott
SSStephan Schultze-Strasser
Stephan Schultze-Strasser
AJAnna Jauch
Anna Jauch
BBBarbara Burwinkel
Barbara Burwinkel
MGManuel Grez
Manuel Grez

17 May 2007 in Stem Cells
Verified
Journal Article
Open access
PDF file
BJBithiah Grace Jaganathan
Bithiah Grace Jaganathan
BRBrigitte Ruester
Brigitte Ruester
LDLars Dressel
Lars Dressel
SSStefan Stein
Stefan Stein
MGManuel Grez
Manuel Grez
RHReinhard Henschler
Reinhard Henschler
Although mesenchymal stromal cells (MSCs) are being increasingly used as cell therapeutics in clinical trials, the mechanisms that regulate their chemotactic migration behavior are incompletely understood. We aimed to better define the ability of the GTPase regulator of cytoskeletal activation, Rho, to modulate migration induction in MSCs in a transwell chemotaxis assay. We found that culture-expanded MSCs migrate poorly toward exogenous phospholipids lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P) in transwell assays. Moreover, plasma-induced chemotactic migration of MSCs was even inhibited after pretreatment with LPA. LPA treatment activated intracellular Rho and increased actin stress fibers in resident MSCs. Very similar cytoskeletal changes were observed after microinjection of a cDNA encoding constitutively active RhoA (RhoAV14) in MSCs. In contrast, microinjection of cDNA encoding Rho inhibitor C3 transferase led to resolution of actin stress fibers, appearance of a looser actin meshwork, and increased numbers of cytoplasmic extensions in the MSCs. Surprisingly, in LPA-pretreated MSCs migrating toward plasma, simultaneous addition of Rho inhibitor C2I-C3 reversed LPA-induced migration suppression and led to improved migration. Moreover, addition of Rho inhibitor C2I-C3 resulted in an approximately 3- to 10-fold enhancement of chemotactic migration toward LPA, S1P, as well as platelet-derived growth factor or hepatocyte growth factor. Thus, inhibition of Rho induces rearrangement of actin cytoskeleton in MSCs and renders them susceptible to induction of migration by physiological stimuli.Disclosure of potential conflicts of interest is found at the end of this article.

21 November 2008 in Circulation Research
Verified
Journal Article
Closed access
TZThomas Ziebart
Thomas Ziebart
CYChang-Hwan Yoon
Chang-Hwan Yoon
TTThomas Trepels
Thomas Trepels
AWAstrid Wietelmann
Astrid Wietelmann
TBThomas Braun
Thomas Braun
DBDittmar Böckler
Dittmar Böckler
Circulating blood–derived vasculogenic cells improve neovascularization of ischemic tissue by a broad repertoire of potential therapeutic actions. Whereas initial studies documented that the cells incorporate and differentiate to cardiovascular cells, other studies suggested that short-time paracrine mechanisms mediate the beneficial effects. The question remains to what extent a physical incorporation is contributing to the beneficial effects of cell therapy. By using the inducible suicide gene thymidine kinase to deplete transplanted cells, we determined the contribution of physical incorporation in 3 animal models. After acute myocardial infarction, depletion of cells 14 days after infusion resulted in a reduction of capillary density and a substantial deterioration of heart function. Likewise, neovascularization of Matrigel plugs and ischemic limbs was significantly suppressed when infused cells were depleted 7 days after infusion. Induction of cell death in the previously transplanted cells reduced perfusion and led to vascular leakage as evidenced by Evans blue extravasation. These results indicate that physical incorporation and persistence of cells contribute to cell-mediated improvement of neovascularization and cardiac function. Long-term paracrine activities and/or cell intrinsic mechanisms may have contributed to the maintenance of functional improvement.

1 March 1996 in Mechanisms of Development
Verified
Journal Article
Closed access
SSStefan Stein
Stefan Stein
RFRüdiger Fritsch
Rüdiger Fritsch
LLLydia Lemaire
Lydia Lemaire
MKMichael Kessel
Michael Kessel

1 July 2016 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Open access
MWMaren Weisser
Maren Weisser
UDUta M. Demel
Uta M. Demel
SSStefan Stein
Stefan Stein
LCLinping Chen-Wichmann
Linping Chen-Wichmann
FTFabien Touzot
Fabien Touzot
MGManuel Grez
Manuel Grez
Defects in phagocytic nicotinamide adenine dinucleotide phosphate oxidase 2 (NOX2) function cause chronic granulomatous disease (CGD), a primary immunodeficiency characterized by dysfunctional microbicidal activity and chronic inflammation. We sought to study the effect of chronic inflammation on the hematopoietic compartment in patients and mice with X-linked chronic granulomatous disease (X-CGD). We used immunostaining and functional analyses to study the hematopoietic compartment in patients with CGD. An analysis of bone marrow cells from patients and mice with X-CGD revealed a dysregulated hematopoiesis characterized by increased numbers of hematopoietic progenitor cells (HPCs) at the expense of repopulating hematopoietic stem cells (HSCs). In patients with X-CGD, there was a clear reduction in the proportion of HSCs in bone marrow and peripheral blood, and they were also more rapidly exhausted after in vitro culture. In mice with X-CGD, increased cycling of HSCs, expansion of HPCs, and impaired long-term engraftment capacity were found to be associated with high concentrations of proinflammatory cytokines, including IL-1β. Treatment of wild-type mice with IL-1β induced enhanced cell-cycle entry of HSCs, expansion of HPCs, and defects in long-term engraftment, mimicking the effects observed in mice with X-CGD. Inhibition of cytokine signaling in mice with X-CGD reduced HPC numbers but had only minor effects on the repopulating ability of HSCs. Persistent chronic inflammation in patients with CGD is associated with hematopoietic proliferative stress, leading to a decrease in the functional activity of HSCs. Our observations have clinical implications for the development of successful autologous cell therapy approaches.